You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pathological response

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Patients

Completed
  • Neoadjuvant Chemotherapy
  • Neoadjuvant therapy
  • Istanbul, Turkey
    AcıbademAH
Nov 21, 2023

Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer

Completed
  • Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
  • CT scan
  • (no location specified)
Sep 13, 2023

Breast Cancer Trial in Angers, Saint-Herblain (Biopsy, Blood samples, Questionnaires)

Not yet recruiting
  • Breast Cancer
  • Biopsy
  • +2 more
  • Angers, France
  • +1 more
Jul 31, 2023

Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

Recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • CT/PET/WSI-based Deep Learning Signature
  • Zunyi, Guizhou, China
  • +2 more
Jun 27, 2023

Head Neck Cancer Trial in Beijin (anti-PD-1 or PD-L1 antibody, postoperative radiaotherapy)

Recruiting
  • Head and Neck Cancer
  • anti-PD-1 or PD-L1 antibody
  • postoperative radiaotherapy
  • Beijin, Beijing, China
    National Cancer Center /National Clinical Research Center for Ca
Mar 18, 2023

Head and Neck Squamous Cell Carcinoma Trial in Zhuhai (dose-reduced radiotherapy)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • dose-reduced radiotherapy
  • Zhuhai, Guangdong, China
    Fifth Affiliated Hospital of Sun Yat-sen University
May 3, 2023

Rectal Cancer Trial (Chemoradiation treatment, 18FDG-PET/MRI scan)

Not yet recruiting
  • Rectal Cancer
  • Chemoradiation treatment
  • 18FDG-PET/MRI scan
  • (no location specified)
Sep 26, 2023

Within 1st Week of Chemotherapy Using Diffuse Optical

Withdrawn
  • Breast Cancer
  • Diffuse Optical Spectroscopy Imaging
  • Costa Mesa, California
  • +2 more
Oct 28, 2022

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Toripalimab (anti-programmed death-1 inhibitor)
  • +4 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Breast Cancer, Radiotherapy Trial in Bologna (SBRT anticipated boost)

Recruiting
  • Breast Cancer
  • Radiotherapy
  • SBRT anticipated boost
  • Bologna, Italy
    IRCCS Azienda Ospedaliero-Universitaria di Bologna
Jan 9, 2023

Melanoma Stage III, Melanoma Trial in Durham, Philadelphia (nivolumab, Ipilimumab)

Recruiting
  • Melanoma Stage III
  • Melanoma
  • Durham, North Carolina
  • +1 more
Mar 25, 2022

Breast Cancer Trial in Shanghai (axillary surgery de-escalation after NAT)

Recruiting
  • Breast Cancer
  • axillary surgery de-escalation after NAT
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 13, 2023

Simple Blood Test to Reduce Unnecessary Adverse Effects From

Not yet recruiting
  • Pathological Response Rate, Circulating Tumour DNA
  • MeD-seq
  • (no location specified)
Sep 6, 2023

Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

Not yet recruiting
  • Melanoma
  • +6 more
  • (no location specified)
Aug 21, 2022

Axillary Lymph Node Dissection, Pathological Complete Response, Neoadjuvant Systemic Therapy Trial in Nanjing (Stained region

Recruiting
  • Axillary Lymph Node Dissection
  • +4 more
  • Stained region Lymph Node Biopsy (SrLNB)
  • Regional lymph node radiotherapy (RNI) including the axilla
  • Nanjing, China
    The First Affiliated Hospital of Nanjing Medical University
Jul 10, 2023

Oral Cancer, Induction Chemo, Programmed Cell Death 1 Inhibitor Trial in Shanghai (drug, procedure, radiation)

Active, not recruiting
  • Oral Cancer
  • +3 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong
Nov 17, 2021

Gastric Cancer Trial in Mykolaiv (Docetaxel, Oxaliplatin, Leucovorin)

Active, not recruiting
  • Gastric Cancer
  • Mykolaiv, Ukraine
    Ukrainian Society of Clinical Oncology
Apr 11, 2022

Early Predict Pathological Complete Response to Neoadjuvant

Recruiting
  • Breast Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Aug 8, 2022

    Pathological Response After Neoadjuvant Treatment on NSCLC

    Recruiting
    • Stage IIIA Non-small Cell Lung Cancer
    • Badalona, Barcelona, Spain
    • +16 more
    Jun 1, 2022

    Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response

    Recruiting
    • Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
    • Vacuum-assisted biopsy
    • Saint-Petersburg, Russian Federation
      Petr Krivorotko
    Jun 14, 2022

    Triple Negative Breast Tumors Trial (Xiaopi granules, Xiaopi decoction, Placebo)

    Not yet recruiting
    • Triple Negative Breast Neoplasms
    • Xiaopi granules
    • +2 more
    • (no location specified)
    Nov 22, 2023

    Histology VABB-Histology Post Surgery Pilot Project

    Active, not recruiting
    • Breast Cancer
    • vacuum-assisted breast biopsy
    • Milan, Italy
      European Instituto of Oncology
    Oct 25, 2021

    Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma Trial in

    Active, not recruiting
    • Anatomic Stage IIIB Breast Cancer AJCC v8
    • +4 more
    • Pembrolizumab
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 30, 2022

    HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • PIK3CA analysis
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Breast Cancer Trial in Ottawa (Trastuzumab)

    Recruiting
    • Breast Cancer
    • Ottawa, Ontario, Canada
      The Ottawa Hospital Cancer Centre
    Apr 26, 2022